FDA OKs Compass dosimetry device

AuntMinnie.com staff writers
Dec 17, 2007

The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to Stockholm-based RaySearch Laboratories and Ion Beam Applications (IBA) of Louvain-la-Neuve, Belgium, for their jointly developed Compass dosimetry device.

Compass is designed to enable medical staff to measure and reconstruct in 3D the radiation dose that was delivered to a patient during the course of treatment.

Related Reading

IBA sells cyclotron to Saudi Arabia, December 4, 2007

IBA, PETLinQ acquire SourceMedical's radiology division, November 26, 2007

IBA to acquire full interest in CIS Bio, September 14, 2007

IBA buries proton hatchet with Optivus, Loma Linda, August 21, 2007

IBA to equip fourth U.S. proton therapy center, July 25, 2007

Copyright © 2007 AuntMinnie.com

Latest in Radiation Oncology/Therapy
Chat Gpt Artificial Intelligence Ai Head
ChatGPT-4 not reliable in cancer patient messaging
April 25, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 2 -- Moving into communities
April 4, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
The rise of theranostics: Part 1 -- Gaining momentum
March 26, 2024
Screenshot (1076)
Researcher outlines radiation oncology workforce challenges
February 23, 2024
Related Stories
2009 01 15 16 03 49 510 Med Phys Web Logo 100
Radiation Oncology/Therapy
Cell survival offers IMRT insight on 'bystander effect'
2007 10 01 09 05 35 706
Radiation Oncology/Therapy
Breast conservation still valid for black women despite higher local relapse rate
2007 10 01 09 05 35 706
Radiation Oncology/Therapy
Local control matters for long-term breast cancer survival
2007 10 01 09 05 35 706
Radiation Oncology/Therapy
Avoiding cardiac irradiation key to breast cancer patients' long-term survival
More in Radiation Oncology/Therapy
ChatGPT-4 not reliable in cancer patient messaging
By Amerigo Allegretto
ChatGPT-4 is not a reliable source for answering patients’ questions regarding cancer and needs physician monitoring.
April 25, 2024
Chat Gpt Artificial Intelligence Ai Head
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 26, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Researcher outlines radiation oncology workforce challenges
By Amerigo Allegretto
Arya Amini, MD, spoke with AuntMinnie.com about a paper he co-authored that outlines workforce challenges being faced by radiation oncologists.
February 23, 2024
Screenshot (1076)
PET/CT radiomics predicts outcomes in women with cervical cancer
By Will Morton
A radiomics nomogram based on F-18 FDG-PET/CT imaging could help clinicians assess long-term outcomes in women undergoing treatment for locally advanced cervical cancer.
February 2, 2024
Representative example of tumor segmentation of radiomics regions of interest (ROI) on axial, coronal, and sagittal PET/CT imaging.
PSMA-PET helps plan treatment in men with relapsed prostate cancer
By Will Morton
PSMA-PET led to management changes in one-third of men receiving salvage radiotherapy for prostate cancer that recurred after radical prostatectomy.
January 31, 2024
Prostate Cancer
FAPI-PET shows promise in head and neck cancer patients
By Will Morton
In a comparative imaging trial, FAPI-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer.
January 26, 2024
PET/CT and MR images of a 72-year-old woman. (A) F-18 FDG-PET images (left and top) and PET/CT images (bottom) shown in coronal, sagittal, and axial views (from left to right), demonstrated a metastatic lymph node of the right neck with intensive metabolic activity (black arrow, SUVmax, 30.1) but presented no evidence for primary tumor. (B) Ga-68 FAPI-PET images (top and right) and PET/CT images (bottom), shown in axial, sagittal, and coronal views (from left to right), also detected metastatic lymph node with high Ga-68 FAPI tracer activity (black arrow, SUVmax, 16.3). There was intensive uptake of Ga-68 FAPI in palate (red arrow, SUVmax, 11.3). (C) T1-weighted, T2-weighted, and contrast-enhanced T1-weighted MRI also presented no evidence for primary tumor. Subsequent surgery confirmed mucoepidermoid carcinoma of palate. Image courtesy of the Journal of Nuclear Medicine.
TerraPower distributes first shipments of Ac-225
By AuntMinnie.com staff writers
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials.
January 24, 2024
Isotopes1
FAPI-PET outperforms FDG-PET in diagnosing pancreatic cancer
By Will Morton
F-18 FAPI-PET/CT is superior to F-18 FDG-PET/CT for diagnosing and staging patients with pancreatic cancer.
January 5, 2024
Typical PET (top), PET/CT (middle), and CT and MR (bottom) images of primary tumor obtained using both radiotracers in representative patients (A and B). Tumor is marked by arrows. DWI = diffusion-weighted imaging. Image courtesy of the Journal of Nuclear Medicine.
PET/CT scans ‘crucial’ in patients with NK/T-cell lymphoma
By Will Morton
PET/CT has significant advantages over conventional methods for lesion detection and staging in patients with natural killer/T-cell lymphoma.
December 22, 2023
A 50-year-old man with recently diagnosed nasal-type NK/T-cell lymphoma underwent an F-18 FDG-PET/CT scan (A–D) for initial staging. Maximum-intensity-projection image (A) shows hypermetabolic lesions in both ethmoid sinus (thin arrow), both cervical lymphatic chains (arrowhead), left upper lung (thick arrow), liver, and spleen. Transaxial images show an F-18 FDG-avid mass in both ethmoid sinus (B). The scan shows intense F-18 FDG radiotracer uptake in left upper lung and uptake in the liver and spleen (CT showed no lesions), suggesting malignancy (C–D). Finally, after the PET/CT scan was done, the patient’s staging was changed from II to IV.
FES-PET better than FDG-PET in breast cancer patients
By Will Morton
In a head-to-head comparison, F-18 fluoroestradiol (FES)-PET/CT was better than standard FDG-PET/CT for the initial staging of estrogen receptor-positive breast cancer patients.
December 21, 2023
Axial PET (a) and axial fusion (b) images of F-18 FES (top) and F-18 FDG (bottom) with concordant uptake of both radiotracers in a left breast mass and left axillary node metastasis in correlation with CT imaging (c). Image courtesy of the European Journal of Hybrid Imaging.
NorthStar to end production of Mo-99
By Will Morton
NorthStar Medical Radioisotopes will shut down its molybdenum-99 (Mo-99) production facilities in Beloit, WI, by the end of 2023.
October 9, 2023
Isotopes
Page 1 of 461
Next Page